

Product datasheet for TL312963V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Flt3 ligand (FLT3LG) Human shRNA Lentiviral Particle (Locus ID 2323)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Flt3 ligand (FLT3LG) Human shRNA Lentiviral Particle (Locus ID 2323)

Locus ID: 2323

Synonyms: FL; FLG3L; FLT3L

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: FLT3LG - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001204502, NM 001204503, NM 001278637, NM 001278638, NM 001459, NM 001459.1,

NM 001459.2, NM 001459.3, NM 001204502.1, NM 001204503.1, NM 001278637.1, NM 001278638.1, BC126293, BC006331, BC011914, BC028001, BC136464, BC144129, NM 001278638.2, NM 001278637.2, NM 001204503.2, NM 001204502.2, NM 001459.4

UniProt ID: P49771

Summary: Dendritic cells (DCs) provide the key link between innate and adaptive immunity by

recognizing pathogens and priming pathogen-specific immune responses. FLT3LG controls the development of DCs and is particularly important for plasmacytoid DCs and CD8 (see MIM

186910)-positive classical DCs and their CD103 (ITGAE; MIM 604682)-positive tissue

counterparts (summary by Sathaliyawala et al., 2010 [PubMed 20933441]).[supplied by OMIM,

Jan 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).